CytomX Therapeutics (CTMX) Common Equity (2016 - 2025)
Historic Common Equity for CytomX Therapeutics (CTMX) over the last 12 years, with Q3 2025 value amounting to $107.4 million.
- CytomX Therapeutics' Common Equity rose 55790.98% to $107.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $107.4 million, marking a year-over-year increase of 55790.98%. This contributed to the annual value of -$456000.0 for FY2024, which is 9903.89% up from last year.
- According to the latest figures from Q3 2025, CytomX Therapeutics' Common Equity is $107.4 million, which was up 55790.98% from $119.9 million recorded in Q2 2025.
- Over the past 5 years, CytomX Therapeutics' Common Equity peaked at $119.9 million during Q2 2025, and registered a low of -$86.6 million during Q1 2023.
- Moreover, its 5-year median value for Common Equity was -$29.7 million (2022), whereas its average is -$9.8 million.
- As far as peak fluctuations go, CytomX Therapeutics' Common Equity tumbled by 1858213.51% in 2022, and later soared by 55790.98% in 2025.
- Over the past 5 years, CytomX Therapeutics' Common Equity (Quarter) stood at -$459000.0 in 2021, then plummeted by 18582.14% to -$85.8 million in 2022, then soared by 44.67% to -$47.4 million in 2023, then surged by 99.04% to -$456000.0 in 2024, then skyrocketed by 23650.22% to $107.4 million in 2025.
- Its Common Equity stands at $107.4 million for Q3 2025, versus $119.9 million for Q2 2025 and $25.0 million for Q1 2025.